Blogs
Advancing Patient Involvement in HTA in Germany: IQWiG’s Evolving Role and Future Directions
Patient involvement in health technology assessment (HTA) has come a long way. Once seen as an optional add-on, it is now a key element of
How Will the EU JCA Change the HTA Process in France?
How the EU JCA is impacting France’s HTA process—key updates on reimbursement, early access, and scientific advice
France’s Healthcare Revolution: Will CEESP Become the New NICE?
Written by Beth McCormick, Senior Analyst France’s cost-effectiveness body, CEESP, currently reviews manufacturer’s economic analyses and determines the potential budget impact on health insurance expenditure.
INCOMING: More ATMPs and the use of innovative payment models in the UK?
Written by Marco Crisci, Senior Analyst The Association of the British Pharmaceutical Industry (ABPI) recently published a report outlining the need for new payment models,
Understanding the Saudi Food & Drug Authority’s Guidelines for Economic Evaluation Studies: Key Recommendations for Pharmaceutical Companies
Written by Johann Sanseáu, Senior Analyst Saudi Arabia has been progressively integrating pharmacoeconomic evaluation methods into the decision-making processes concerning the pricing and reimbursement of
Growing concerns over proposed OMP legislation changes in Europe
Written by Iro Malekou, Senior Analyst & Srishti Gupta, Senior Consultant Emails: imalekou@partners4access.com, sgupta@partners4access.com Over a year ago, the European Commission (EC) set out to
The World’s First CRISPR Gene Therapy Approved in UK!
Vertex and CRISPR Therapeutics’ Casgevy became the first CRISPR gene therapy to be approved in the world after the UK’s MHRA granted conditional approval. Casgevy is indicated for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, with the hope of being a potentially curative therapy for patients
Clinical trials for rare diseases: What can we expect?
Written by Marco Sancandi, PhD, Analyst. Email: msancandi@partners4access.com Rare diseases, individually infrequent but collectively prevalent, are in the spotlight as scientists strive to develop safer
Special Reimbursement Schemes Could Improve Access to Innovative Drugs in France and Canada
Written by Angeliki Meletsi, Analyst Email: ameletsi@partners4access.com The time taken to get access and reimbursement for new drugs is a key area of concern that
